Replies to post #57426 on Biotech Values

[jbog]

Master,

I'm wondering if we're underestimating the FDA's reaction to Roche's xeloda/bev filing using the n016966 trial. It's going to be interesting what the fda does about the lack of rr or os and the miniscule pfs data. N016966 isn't nearer as persuading as breast.